Recent Phase 3 trial results provide three critical insights for healthcare providers and families affected by achondroplasia. First, infigratinib represents the first oral disease-modifying therapy for this condition, offering a 50–60% improvement in growth velocity through a weight-adjusted oral dosing regimen. Second, growth gains are accompanied by documented functional improvements in mobility and activities of daily living, suggesting benefits beyond linear measurement alone. Third, while long-term safety data collection through age 18 remains ongoing, interim safety assessments support the drug’s tolerability in the paediatric population studied.
Expectations for regulatory decisions in 2024–2025 suggest potential clinical availability within the next 12–18 months. Clinicians managing achondroplasia should familiarise themselves with infigratinib’s mechanism and trial outcomes to facilitate informed discussions with families regarding emerging therapeutic options. This development marks a paradigm shift in rare genetic skeletal dysplasia management.
Read the full article on GMJ Newsroom.
Was this article helpful?
